Saturday, 21 October 2017 10:51

Anticoagulation news items. Week commencing 9th October and 16th October 2017

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study

Blood

Over median duration of 2.37 years, 259 patients (85.8%) achieved response (platelets ≥50×109/L at least once in absence of rescue) and 133 of 257 (52%) achieved continuous response ≥25 weeks. Rate of thromboembolic events (6%) did not increase with treatment duration past 1 year.

 

Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study

British Medical Journal

Retrospective study (n=12,489 on DOACs and 47,036 on warfarin in Canada and US with new diagnosis of venous thromboembolism) found treatment with DOACs, compared with warfarin, was not linked to increased risk of major bleeding or all-cause mortality in first 90 days of treatment.

 

Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year-old man

British Journal of Clinical Pharmacology

Timeline for increase in trough level of cyclosporine after introduction of ticagrelor (TC) for unstable angina was considered consistent with appearance of an interaction, thought to be due to inhibition of CYP3A4 and P-glycoprotein by TC, which was managed by cessation of TC.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services